Condensed Interim Consolidated Financial Statements

# Justera Health Ltd. (formerly ScreenPro Security Inc.)

For the nine months ended September 30, 2023

(Unaudited)

(Expressed in Canadian dollars)

## Notice to Reader

The accompanying unaudited condensed interim consolidated financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these unaudited condensed consolidated interim financial statements in accordance with standards established by the Chartered Professional Accountants of Canada for a review of interim financial statements by an entity's auditor.

### Justera Health Ltd. (formerly ScreenPro Security Inc.) Condensed Interim Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

(Unaudited)

		As at September 30,	As at December 31,
		2023 \$	2022 \$
		· · · · ·	
ASSETS			
CURRENT			
Cash		10,237	437,415
Accounts receivable		880,732	74,398
Sales tax recoverable		77,853	8,079
Inventory [note 4]		161,037	462,079
Prepaid expenses		324,193	85,015
		1,454,052	1,066,986
<b>DEPOSIT</b> [note 8]		10,000	10,000
PROPERTY AND EQUIPMENT [note	2 5]	76,053	506,240
RIGHT-OF-USE ASSET [note 8]		61,426	119,464
<b>INTANGIBLE ASSETS</b> [note 6]		529,167	582,084
GOODWILL [note 6]		2,675,998	2,675,998
Total assets		4,806,696	4,960,772
LIABILITIES AND SHAREHOLDER CURRENT Accounts payable and accrued liabilities Current portion of lease liabilities [note	S	1,397,951 62,025	3,554,404 79,484
Current portion of lease nabilities [note	0]	1,459,976	3,633,888
LONG-TERM ACCOUNTS PAYABLI	F	4,753,308	5,055,000
LEASE LIABILITIES [note 8]		ч,755,500	41,180
Total liabilities		6,213,284	3,675,068
SHAREHOLDERS' EQUITY			
Share capital <i>[note 9]</i>		15,712,036	15,592,036
Options reserve		68,826	
Warrants reserve		2,142,182	2,142,182
Accumulated deficit		(19,329,632)	(16,448,514)
Total shareholders' equity		(1,406,588)	1,285,704
Total liabilities and shareholders' equit	V	4,806,696	4,960,772
<b>`</b>	درو،)	"• <b>·</b> "	/· · · · · · ·
Approved on behalf of the Board	Director (Signed)	Director (Sign	ed)
	Director (Signed)	Director (Sigi	icu)

### Justera Health Ltd. (formerly ScreenPro Security Inc.) Condensed Interim Consolidated Statements of Loss and Comprehensive Loss

(Expressed in Canadian Dollars)

(Unaudited)

	months ended September 30, 2023	September 30, 2022	months ended September 30, 2023	months ended September 30, 2022
	\$	\$	\$	\$
SALES	473,463	2,882,900	1,449,045	11,203,259
COST OF SALES	(130,836)	(3,163,589)	(928,607)	(10,030,368)
GROSS PROFIT	342,627	(280,689)	520,438	1,172,891
EXPENSES				
Consulting fees [note 7]	169,582		183,236	
Depreciation [notes 5, 6 and 8]	132,144	142,416	386,665	919,301
General and administrative [note 7]	400,491	245,542	725,440	747,905
Marketing	136,138	113,011	229,173	168,637
Professional services	371,010	830,521	1,068,118	3,095,269
Salaries [note 7]	162,960	397,785	676,360	1,120,425
Share-based compensation [note 9]			68,826	
NET LOSS BEFORE OTHER ITEMS OTHER ITEMS	(1,029,698)	(2,009,964)	(2,817,380)	(4,878,646)
Gain on sale of property and equipment [note 5]	426,207		426,207	
Excess consideration paid [note 12]	(489,945)	_	(489,945)	_
NET LOSS AND COMPREHENSIVE LOSS	(1,093,436)	(2,009,964)	(2,881,118)	(4,878,646)
Basic and diluted earnings per share	(0.01)	(0.02)	(0.02)	(0.06)
Weighted average number of common shares - basic and diluted	121,728,769	100,472,247	119,772,247	81,480,185

## Justera Health Ltd. (formerly ScreenPro Security Inc.) Condensed Interim Consolidated Statements of Changes in Shareholders' Equity

(Expressed in Canadian Dollars)

(Unaudited)

	Number of	Share capital	Options reserve	Warrants reserve	Accumulated deficit	Total
	shares	\$	\$	\$	\$	\$
Balance, December 31, 2021	41,638,916	11,073,403	—	969,332	(11,196,732)	846,003
Shares issued for acquisition [notes 9 and 12]	58,833,331	6,500,000	—	2,091,665		8,591,665
Net loss for the period					(4,878,646)	(4,878,646)
Balance, September 30, 2022	100,472,247	17,573,403	_	3,060,997	(16,075,378)	4,559,022
Balance, December 31, 2022	118,772,247	15,592,036	_	2,142,182	(16,448,514)	1,285,704
Shares issued for acquisition [notes 9 and 12]	4,000,000	120,000	_	—		120,000
Share-based compensation			68,826			68,826
Net loss for the period			_		(2,881,118)	(2,881,118)
Balance, September 30, 2023	122,772,247	15,712,036	68,826	2,142,182	(19,329,632)	(1,406,588)

### Justera Health Ltd. (formerly ScreenPro Security Inc.) Condensed Interim Consolidated Statements of Cash Flows

(Expressed in Canadian Dollars)

(Unaudited)

	For the nine months	For the nine months
	ended September 30,	ended September 30,
	2023	2022
	\$	\$
OPERATING ACTIVITIES		
Net loss	(2,881,118)	(4,878,646)
Items not affecting cash:		
Accretion and interests	8,561	9,462
Depreciation	386,665	919,301
Share-based compensation	68,826	
Gain on sale of property and equipment	(426,207)	
Excess consideration paid	489,945	
Changes in non-cash working capital balances:		
Accounts receivable	(145,595)	(216,082)
Harmonized sales tax recoverable	(69,774)	(66,368)
Inventory	301,042	1,956,104
Prepaid expenses	(239,178)	49,724
Accounts payable and accrued liabilities	2,146,855	2,097,854
Cash (used in) provided by operating activities	(359,978)	(128,651)
INVESTING ACTIVITIES		
Acquisition of AddBio, net of cash received		1,069,776
Acquisition of NatureVan, net of cash received		(486,686)
Purchase of property and equipment		(270,019)
Cash provided by investing activities		313,071
FINANCING ACTIVITIES		
Lease payments	(67,200)	(45,600)
Cash used in financing activities	(67,200)	(45,600)
INCREASE (DECREASE) IN CASH	(427,178)	138,820
CASH - BEGINNING OF PERIOD	437,415	207,789
CASH - END OF PERIOD	10,237	346,609
Supplementary cash flow information		
Interest income		
Income tax paid		

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### **1. NATURE OF BUSINESS**

Justera Health Ltd. (formerly ScreenPro Security Inc.) (the "Company") is incorporated under the laws of the Province of Ontario. The Company's common shares are listed on the Canadian Securities Exchange under the trading symbol "SCRN".

While these consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") on a going concern basis that presumes the realization of assets and discharge of liabilities in the normal course of business, there are material uncertainties related to adverse conditions and events that cast significant doubt on the Company's ability to continue as a going concern.

During the nine months ended September 30, 2023, the Company incurred a loss of \$2,881,118 (2022 - \$4,878,646) and, as of that date, the Company had accumulated deficit of \$19,329,632 (December 31, 2022 – deficit of \$16,448,514) and a working capital deficit of \$5,924 (December 31, 2022 – deficit of \$2,566,902). The Company's continuing operations as intended are dependent upon its the ability to raise additional funds, investor sentiment and financial market conditions, all of which may be impacted by the uncertainties in the market. Should the Company be unable to secure additional financing, the Company may be unable to discharge its net liabilities. These uncertainties may cast significant doubt upon the Company's ability to continue as a going concern.

The office address of the Company is 2300 Yonge Street, Suite 2802, Toronto, Ontario, M4P 1E4.

In March 2020, the World Health Organization declared a global pandemic related to the virus known as COVID-19. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It has also disrupted the normal operations of many businesses. The Company's business began as a result of this disruption. The Company's business related to COVID-19 has been declining since 2022.

### 2. BASIS OF PRESENTATION

#### 2.1 Basis of presentation and statement of compliance

These condensed consolidated interim financial statements for the Company for the nine months ended September 30, 2023 have been prepared in accordance with International Accounting Standards ("IAS") 34 – Interim Financial Reporting of the International Financial Reporting Standards ("IFRS"), issued by the International Accounting Standards Board ("IASB"). Accordingly, certain information and footnote disclosure normally included in annual financial statements prepared in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB"), have been omitted or condensed.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

The preparation of financial statements in accordance with IAS 34 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements have been set out in the notes to the Company's financial statements for the year ended December 31, 2022. These condensed consolidated interim financial statements should be read in conjunction with the Company's financial statements for the period ended December 31, 2022.

These condensed consolidated interim financial statements were approved and authorized for issuance by the Company's Board of Directors on November 29, 2023. These condensed interim financial statements are presented in Canadian dollars which is also the Company's functional currency. The accounting policies have been applied consistently in these financial statements, unless otherwise indicated.

### 2.2 Principles of consolidation

The Company's wholly owned operating subsidiaries include:

	Jurisdiction of		
Name of the entity	incorporation	Functional currency	Principal activity
ScreenPro Security Ltd. ("ScreenPro Ltd")	Canada	Canadian Dollar	Health Care
GoStop Inc. ("GoStop")	Canada	Canadian Dollar	Health Technology
Justera Wellness Inc. ("Justera Wellness")	Canada	Canadian Dollar	Health Care
Add Biomedical Inc. ("AddBio")	Canada	Canadian Dollar	Health Care
NatureVan Nutrition Ltd. ("NatureVan")	Canada	Canadian Dollar	Health Care

Intercompany balances and transactions are eliminated upon consolidation and preparation of these consolidated financial statements.

#### 2.3 Basis of measurement

These consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair value, as explained. The financial statements are presented in Canadian dollars which is the presentation and functional currency of the Company.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### **3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

### 3.1 Significant accounting judgments and estimates

The application of the Company's accounting policies require management to use estimates and judgments that can have significant effect on the revenues, expenses, comprehensive income (loss), assets and liabilities recognized and disclosures made in the financial statements.

Management's best estimates concerning the future are based on the facts and circumstances available at the time estimates are made. Management uses historical experience, general economic conditions and assumptions regarding probable future outcomes as the basis for determining estimates. Estimates and their underlying assumptions are reviewed periodically and the effects of any changes are recognized immediately. Actual results could differ from the estimates used.

Management's budget and strategic plans are fundamental information used as a basis for estimates necessary to prepare financial information. Management tracks performance as compared to the budget and significant variances in actual performance are a key trigger to assess whether certain estimates used in the preparation of financial information must be revised.

#### 3.2 Changes in accounting standard

The Company has evaluated all recent accounting pronouncements up to the date of issuance of these financial statements, and conclude that these pronouncements are not expected to have any significant impact on the Company's financial statements.

### **4. INVENTORY**

	As at September 30, 2023	As at December 31, 2022
	\$	\$
Covid-19 test kits under laboratory testing	-	301,711
NatureVan – finished goods	161,037	160,368
	161,037	462,079

The cost of inventory included in the cost of sales was \$277,577 (2022 - \$3,773,080).

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### 5. PROPERTY AND EQUIPMENT

	Equipment	Vehicles	Total
	\$	\$	\$
Cost:			
As at December 31, 2021	1,038,166	231,771	1,269,937
Additions	117,778		117,778
As at December 31, 2022	1,155,944	231,771	1,387,715
Additions	80,055		80,055
Disposals	(1,155,944)	(108,396)	(1,264,340)
As at September 30, 2023	80,055	123,375	203,430
Accumulated depreciation:			
As at December 31, 2021	311,503	72,213	383,716
Depreciation	385,314	112,445	497,759
As at December 31, 2022	696,817	184,658	881,475
Depreciation	237,163	38,547	275,710
Disposals	(929,978)	(99,830)	(1,029,808)
As at September 30, 2023	4,002	123,375	127,377
Net book value:			
As at December 31, 2022	(616,762)	(61,283)	(678,045)
As at September 30, 2023	76,053		76,053

During the nine months ended September 30, 2023, the Company sold certain equipment for \$660,739, included in accounts receivable at September 30, 2023, resulting in a gain of \$426,207 for the period.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### 6. INTANGIBLE ASSET AND GOODWILL

	Developed technologies	Goodwill	Total
	\$	\$	\$
Cost:			
As at December 31, 2021	2,117,600	602,165	2,719,765
Additions	635,000	2,073,833	2,708,833
As at December 31, 2022 and September 30, 2023	2,752,600	2,675,998	5,428,598
Accumulated depreciation:			
As at December 31, 2021	1,624,460		1,624,460
Depreciation	546,056		546,056
As at December 31, 2022	2,170,516		2,170,516
Depreciation	52,917		52,917
As at September 30, 2023	2,223,433		2,223,433
Net book value:			
As at December 31, 2022	582,084	2,675,998	3,258,082
As at September 30, 2023	529,167	2,675,998	3,205,165

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### 7. RELATED PARTY TRANSACTIONS

Related parties are defined as management and principal shareholders of the Company and/or members of their immediate family and/or other companies and/or entities in which a principal shareholder, director or senior officer is a principal owner or senior executive.

Related party transactions, with entity with common management and shareholders, are as follows:

	For the nine months ended September 30, 2023 \$	For the nine months ended September 30, 2022 \$
Salaries paid to current and former officers and directors	90,000	488,333
Consulting fees paid to current and former officers and directors	45,000	834,500

Included in accounts payable at September 30, 2023 was \$2,260 (December 31, 2022 - \$Nil) due to a company controlled by an officer of the Company.

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company, including directors, advisory board members, officers of the Company.

### 8. RIGHT-OF-USE ASSET AND LEASE LIABILITIES

During the thirteen months ended December 31, 2021, the Company entered into a lease agreement with a company controlled by a former director of the Company. The lease contract contained a deposit in the amount of \$10,000 that will be applied for the rent of the last two months the lease term. The lease expires in March 2024.

During the year ended December 31, 2022, the Company entered into a lease agreement with an arm's length party for NatureVan. The lease is \$2,300 per month and expires in December 2024.

#### **Right-of-use asset**

	\$
Balance at December 31, 2021	119,929
Addition	62,720
Amortization charge for the year	(63,185)
Balance at December 31, 2022	119,464
Amortization charge for the year	(58,038)
Balance at September 30, 2023	61,426

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

#### Lease liability

\$
120,829
62,720
16,415
(79,300)
120,664
8,561
(67,200)
62,025
62,025

When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate of 12%.

Future lease payments are as follows:

Year ended December 31, 2023	\$17,300
Year ended December 31, 2024	\$43,200

#### 9. SHARE CAPITAL

#### a) Authorized:

Unlimited number of common shares, one votes per share, without par value

#### b) Issued:

On February 22, 2022, the Company acquired AddBio and issued 33,000,000 common shares valued at \$2,475,000 (note 12).

On May 1, 2022, the Company acquired NatureVan and issued 25,833,331 common shares valued at \$1,420,833 (note 12).

On December 14, 2022, the Company issued 9,700,000 units at \$0.05 per unit for gross proceeds of \$485,000. Each unit consisted of one common share and one share purchase warrant exercisable at \$0.05 for 18 months from the date of issuance. The Company paid finder's fees of \$1,200.

#### Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

On December 14, 2022, the Company issued 8,600,000 common shares at \$0.05 per share for gross proceeds of \$430,000.

On July 24, 2023, the Company acquired the assets of Juillet Wellness Centre and issued 4,000,000 common shares valued at \$120,000 in escrow (note 12).

#### **Stock Options**

In January 2023, the Company granted 4,800,000 stock options to certain officers, directors and consultants of the Company exercisable at \$0.05 per share expiring on January 26, 2025. The options vested immediately.

The fair value of the stock options granted in January 2023 was \$68,826, recorded as share-based compensation for the nine months ended September 30, 2023. The fair value was calculated using the Black-Scholes option pricing model, using the following assumptions: expected life of the options: 2 years, expected volatility: 184.66%, expected dividend yield rate: Nil, and risk-free interest rate: 3.65%.

As at September 30, 2023, 4,800,000 stock options remain outstanding and exercisable.

#### Warrants

The changes in the Company's warrants for the year ended December 31, 2022 and the nine months ended September 30, 2023 are as follows:

	Number of warrants	Weighted average exercise price
Balance, December 31, 2021	2,205,754	\$1.40
AddBio acquisition (note 12)	33,000,000	\$0.15
NatureVan acquisition (note 12)	25,833,331	\$0.07
GoStop warrants expired	(2,000,000)	\$1.50
Issued from a private placement	9,700,000	\$0.05
Expired	(74,080)	\$0.20
Balance, December 31, 2022	68,665,005	\$0.11
Expired	(131,674)	\$0.30
Balance, September 30, 2023	68,533,331	\$0.11

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

As at September 30, 2023, the Company had the following warrants outstanding and exercisable:

Number of warrants	Exercise price	Expiry date
33,000,000	\$0.15	March 18, 2024
25,833,331	\$0.07	May 13, 2024
9,700,000	\$0.05	June 14, 2024

### **10. FINANCIAL RISK FACTORS**

#### Fair Value

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits from the asset's highest and best use or by selling it to another market participant that would utilize the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy. This is described, as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

• Level 1 inputs are quoted prices in active markets for identical assets or liabilities at the measurement date.

• Level 2 inputs are observable inputs other than quoted prices included within Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical assets or liabilities in markets that are not active, or other inputs that are observable directly or indirectly.

• Level 3 inputs are unobservable inputs for the asset or liability that reflect the reporting entity's own assumptions and are not based on observable market data.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

Unless otherwise noted, the carrying value of cash, accounts receivable, accounts payable and accrued liabilities approximates fair value for each financial instrument.

#### **Financial Risk Management**

The Company is exposed to credit risk and liquidity risk. The Company's management oversees the management of these risks. The Company's management is supported by the Board that advises on financial risks and the appropriate financial risk governance framework for the Company. The Company's financial risk activities are governed by appropriate policies and procedures and that financial risks are identified, measured and managed in accordance with Company policies and the Company risk appetite.

#### (a) Credit Risk

Credit risk is the risk of unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations. Financial instruments which potentially subject the Company to concentrations of credit risk consist of cash and accounts receivable. The cash consists of money held in a reputable Canadian bank. To reduce its credit risk from its accounts receivable, the Company reviews credit history of new clients before extending credit. Historically, there has been no collection issue with any of the Company's customers.

#### (b) Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting obligation associated with financial liabilities. The Company is exposed to this risk mainly in respect of its accounts payable and accrued liabilities. The Company's approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. The Company manages liquidity risk through obtaining financing from its shareholders. At September 30, 2023, the Company had a working capital deficiency of \$5,924 (2022 – deficiency of \$2,566,902) and, as a result, the Company will need additional financing in the future.

#### **11. CAPITAL MANAGEMENT**

The Company's objectives when managing capital are to maintain a strong capital base so as to maintain investor, creditor and market confidence and sustain future development of the business. The capital of the Company consists of equity.

The Company manages its capital structure and makes adjustments in light of the changes in its economic environment and the risk characteristics of the Company's assets. To effectively manage the Company's capital requirements, the Company has in place planning, budgeting and forecasting process to help determine the funds required to ensure the Company has the appropriate liquidity to meet its operating and growth objectives. There were no externally imposed capital requirements to which the Company is subject as at September 30, 2023.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

### **12. ACQUISTIONS**

#### Add Biomedical Inc.

In February 2022, the Company announced a proposed acquisition of Add Biomedical Inc., a biomedical screening company with the initial focus on breast cancer detection. In March 2022, the Company completed the acquisition of all of the issued and outstanding shares of Add Bio. Pursuant to the Share Purchase Agreement, the Company issued 33,000,000 units of the Company (note 9), each unit consisting of one common share and one common share purchase warrant. Each warrant exercisable to purchase one common share at an exercise price of \$0.15 per share for 24 months.

The purchase price had a total fair value of \$3,038,001 calculated as follows: \$2,475,000 related to 33,000,000 common shares of the Company and \$563,001 related to 33,000,000 warrants determined by the Black-Scholes option pricing model using the following assumptions: (i) expected warrant life of 2.00 years; (ii) risk free rate of 1.89%; (iii) dividend yield of nil; and (iv) expected volatility of 75.71%.

The acquisition of AddBio was accounted for as an asset acquisition consistent with IFRS 2 – Shares based payments, as it did not meet the definition of a business under IFRS 3 – Business combination. During the year ended December 31, 2022, the Company recognized an intangible asset in the amount of \$635,000 related to AddBio's developed technology (note 6).

The allocation of the purchase consideration is as follows:

	Amount
Purchase consideration	
Common shares	\$ 2,475,000
Warrants	563,001
Total	\$ 3,038,001
Fair value of assets acquired	
Cash	\$ 1,069,776
Intangible asset	635,000
Total identifiable net assets acquired	1,704,776
Excess consideration paid expensed	1,333,225
Total	\$ 3,038,001

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

#### NatureVan Nutrition Ltd.

On May 1, 2022, the Company completed the acquisition of NatureVan, an e-commerce and retail business with natural health supplement products. The acquisition of NatureVan expands the Company's opportunities in the health and wellness industry. The Company was issued 25,833,331 units of the Company (note 9), each unit consisting of one common share and one common share purchase warrant. Each warrant exercisable to purchase one common share at an exercise price of \$0.07 per share for 24 months.

The purchase price had a total fair value of \$2,389,682 calculated as follows: \$650,000 paid in cash, \$1,420,833 related to 25,833,331 common shares of the Company and \$318,849 related to 25,833,331 warrants determined by the Black-Scholes option pricing model using the following assumptions: (i) expected warrant life of 2.00 years; (ii) risk free rate of 2.73%; (iii) dividend yield of nil; and (iv) expected volatility of 52.31%.

The acquisition of NatureVan was accounted for as a business combination, in which the assets acquired and the liabilities assumed are recorded at their estimated fair values.

The allocation of the purchase consideration is as follows:

	Amount
Purchase consideration	
Cash	\$ 650,000
Common shares	1,420,833
Warrants	318,849
Total	\$ 2,389,682
Fair value of assets acquired and liabilities assumed	
Cash	\$ 163,314
Accounts receivable and other receivables	7,096
Inventory	149,074
Prepaid expenses	2,300
Accounts payable and accrued liabilities	(5,935)
Total identifiable net assets assumed	315,849
Goodwill	2,073,833
Total	\$ 2,389,682

Goodwill recognized comprises the assembled workforce and their knowledge, regulatory affairs and expected revenue growth and future market development.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

NatureVan had limited history of operations and, as a result, the Company's pro-forma information presenting the combined results as if the acquisition of NatureVan was completed at the beginning of the period would not be significantly different from these results presented for the year ended December 31, 2022.

#### Juillet Wellness Centre

In July 2023, the Company completed the acquisition of Juillet Wellness Centre located in British Columbia, Canada.

The Company acquired all or substantially all of the assets of the business pursuant to an asset purchase agreement made on July 13, 2023, as amended on July 21, 2023. The purchase price of \$570,000, subject to adjustments, is as follows:

- i. \$120,000 through the issuance of an aggregate of 4,000,000 common shares of the Company issued at a price of \$0.03 per share which are subject to both a statutory hold period of 4 months plus a day and an up to 1 year hold back to address possible post-closing adjustments; and
- ii. The assumption by the Company of certain lease liabilities in respect of the business, up to \$450,000.

The Company recorded the fair value of equipment purchased of \$80,055 (preliminary) and, as a result, the difference of \$489,945 (preliminary) was recognized as excess consideration paid related to this acquisition.

#### **13. CONTINGENCY**

A vendor commenced a claim against the Company in the Ontario Small Claims Court claiming damages of \$16,055. The Company has defended the claim. The claim remains outstanding as of September 30, 2023. The dispute is in its early stages and the outcome of the matter is undeterminable at this time.

#### **14. SUBSEQUENT EVENTS**

#### Life Offering

The Company closed its non-brokered private placement offering, pursuant to the listed issuer financing exemption ("LIFE Offering"), resulting in the issuance of 33,973,336 common shares of the Company at a price of \$0.03 per share for aggregate gross proceeds of \$1,019,200. The Company paid aggregate cash commissions of \$33,672 to finders in connection with the LIFE Offering.

Notes to Condensed Consolidated Interim Financial Statements

For the nine months ended September 30, 2023 and 2022 (Expressed in Canadian Dollars) (Unaudited)

#### **Triniti acquisition**

The Company completed the acquisition of all of the shares of Triniti Trading Corp. an authorized distributor of TonyMoly products in Canada. The aggregate purchase price of \$328,000, was satisfied by: (a) a cash payment on closing of \$60,000; (b) assumption of \$40,000 loan; and (c) the issuance of an aggregate of 4,060,000 Common Shares of the Company at a deemed price of \$0.05 per share ("Payment Shares"). A further cash payment of \$65,000 is due 50 days from the closing date.

The Payment Shares are subject to voluntary restrictions on transfer and become free trading as follows: (a) 25% on the date that is 4 months and 1 day from date of issuance; (b) 25% on the date that is 6 months from date of issuance; (c) 25% on the date that is 9 months after issuance; and (d) 25% on the date that is 12 months after issuance.